Straits Times Index
3,332.03 -11.32 (-0.34%) Nikkei
39,583.08 +241.54 (+0.61%) Hang Seng
17,740.17 +23.70 (+0.13%) FTSE 100
8,179.68 -45.65 (-0.55%) Bitcoin USD
61,538.82 +826.23 (+1.36%) CMC Crypto 200
1,284.05 +0.22 (+0.02%)
EDIT Jan 2025 5.000 put
| Previous close | 1.1200 |
| Open | 1.1800 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 5.00 |
| Expiry date | 2025-01-17 |
| Day's range | 1.1200 - 1.1800 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Insider MonkeyWhat Makes Editas Medicine, Inc. (EDIT) One of the Best Small-Cap Stocks with Highest Upside Potential?
We recently compiled a list of the Top 10 Small-Cap Stocks with Highest Upside Potential. In this article, we are going to take a look at where Editas Medicine, Inc. (NASDAQ:EDIT) stands against the other small-cap stocks. Small-cap stocks are companies with a market capitalization of somewhere between $250 million and $2 billion. They are usually […]
ZacksEditas (EDIT) Reports Upbeat New Data From Reni-Cel Studies
Editas (EDIT) reports positive new safety and efficacy data from the RUBY and EdiTHAL studies evaluating its investigational gene therapy, reni-cel, for SCD and TDT, respectively.
GlobeNewswireEditas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
All patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel) infusion Patients had early normalization of total hemoglobin with a mean within the normal range at >14 g/dL and rapid and sustained improvements in fetal hemoglobin well above levels of >40%. Reni-cel was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant EHA RUBY oral pres
